{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:26:08Z","timestamp":1780701968814,"version":"3.54.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3622,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Primary biliary cirrhosis (PBC) recurs after orthotopic liver transplantation (OLT) in up to one-third of patients. These patients are typically asymptomatic, can be identified by abnormal liver biochemistries, and have evidence of histologic recurrence on liver biopsy. The effect of treatment on recurrence has not been determined. This pilot study evaluates the factors associated with recurrent PBC and describes our experience using ursodeoxycholic acid treatment in this patient population. Forty-eight patients with PBC were followed for at least 1 yr post-OLT, and 27 patients (56%) developed abnormal serum alkaline phosphatase. Seventeen patients (35%) had evidence of recurrent PBC by liver biopsy. Patients with recurrent PBC had a trend toward longer warm ischemia times and more episodes of acute cellular rejection in the first year posttransplant, but this was not significant in multivariate analysis. Donor or recipient age, donor and recipient cytomegalovirus status, and dose of immunosuppression did not correlate with recurrence of PBC. Those patients diagnosed with recurrent PBC were placed on ursodeoxycholic acid, 15 mg\/kg daily, with improvement in serum alkaline phosphatase in the majority. In conclusion, recurrent PBC is not infrequent post-OLT, and ursodeoxycholic acid can be used with some benefit post-OLT. Treatment effects on long-term survival are not known.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20511","type":"journal-article","created":{"date-parts":[[2005,9,23]],"date-time":"2005-09-23T17:46:50Z","timestamp":1127497610000},"page":"1252-1257","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":74,"title":["Recurrent Primary Biliary Cirrhosis"],"prefix":"10.1097","volume":"11","author":[{"given":"Jennifer E.","family":"Guy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20250124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/pgmj.73.856.75","article-title":"Ursodeoxycholic acid in the treatment of liver diseases.","volume":"73","author":"Saksena","year":"1997","journal-title":"Postgrad Med J"},{"key":"R2-18-20250124","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0016-5085(97)70239-7","article-title":"Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei.","volume":"112","author":"Setchell","year":"1997","journal-title":"Gastroenterology"},{"key":"R3-18-20250124","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/0016-5085(93)90653-T","article-title":"Molecular aspects of membrane stabilization by ursodeoxycholate. see comment.","volume":"104","author":"Guldutuna","year":"1993","journal-title":"Gastroenterology"},{"key":"R4-18-20250124","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0016-5085(92)90855-S","article-title":"Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse.","volume":"103","author":"Calmus","year":"1992","journal-title":"Gastroenterology"},{"key":"R5-18-20250124","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","article-title":"Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.","volume":"8","author":"Paumgartner","year":"2004","journal-title":"Clin Liver Dis"},{"key":"R6-18-20250124","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"R7-18-20250124","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","article-title":"Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis.","volume":"99","author":"Combes","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R8-18-20250124","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"R9-18-20250124","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis.","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"key":"R10-18-20250124","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R11-18-20250124","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"R12-18-20250124","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R13-18-20250124","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"R14-18-20250124","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"R15-18-20250124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"key":"R16-18-20250124","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"R17-18-20250124","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"R18-18-20250124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/jhep.2001.20894","article-title":"Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center.","volume":"33","author":"Liermann Garcia","year":"2001","journal-title":"Hepatology"},{"key":"R19-18-20250124","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00007890-200201270-00012","article-title":"Benefit of transplantation in primary biliary cirrhosis between 1985-1997.","volume":"73","author":"Tinmouth","year":"2002","journal-title":"Transplantation"},{"key":"R20-18-20250124","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/jlts.2003.50096","article-title":"Recurrent primary biliary cirrhosis.","volume":"9","author":"Neuberger","year":"2003","journal-title":"Liver Transpl"},{"key":"R21-18-20250124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198201073060101","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation.","volume":"306","author":"Neuberger","year":"1982","journal-title":"N Engl J Med"},{"key":"R22-18-20250124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/jlts.2003.36392","article-title":"Liver transplantation for primary biliary cirrhosis: a long-term pathologic study.","volume":"9","author":"Khettry","year":"2003","journal-title":"Liver Transpl"},{"key":"R23-18-20250124","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history.","volume":"9","author":"Sylvestre","year":"2003","journal-title":"Liver Transpl"},{"key":"R24-18-20250124","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-8278(05)80244-2","article-title":"Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation.","volume":"18","author":"Hubscher","year":"1993","journal-title":"J Hepatol"},{"key":"R25-18-20250124","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis.","volume":"40","author":"Poupon","year":"2004","journal-title":"Hepatology"},{"key":"R26-18-20250124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","article-title":"Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.","volume":"29","author":"Pasha","year":"1999","journal-title":"Hepatology"},{"key":"R27-18-20250124","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis.","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"R28-18-20250124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.","volume":"24","author":"Corpechot","year":"2004","journal-title":"Liver Int"},{"key":"R29-18-20250124","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.510250103","article-title":"et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression.","volume":"25","author":"Van Norstrand","year":"1997","journal-title":"Hepatology"},{"key":"R30-18-20250124","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.48.3.397","article-title":"HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility.","volume":"48","author":"Donaldson","year":"2001","journal-title":"Gut"},{"key":"R31-18-20250124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1089-3261(05)70005-2","article-title":"Pathogenesis of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangiopathy.","volume":"2","author":"Peters","year":"1998","journal-title":"Clin Liver Dis"},{"key":"R32-18-20250124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1399-0039.1994.tb02303.x","article-title":"Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis.","volume":"43","author":"Begovich","year":"1994","journal-title":"Tissue Antigens"},{"key":"R33-18-20250124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.1840070516","article-title":"Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens.","volume":"7","author":"Gores","year":"1987","journal-title":"Hepatology"},{"key":"R34-18-20250124","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/0016-5085(91)90090-8","article-title":"HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis.","volume":"101","author":"Manns","year":"1991","journal-title":"Gastroenterology"},{"key":"R35-18-20250124","first-page":"112","article-title":"DNA polymorphism of HLA class II genes in primary biliary cirrhosis.","volume":"35","author":"Morling","year":"1992","journal-title":"Immunogenetics"},{"key":"R36-18-20250124","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.1840160616","article-title":"Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB10402 haplotype.","volume":"16","author":"Underhill","year":"1992","journal-title":"Hepatology"},{"key":"R37-18-20250124","first-page":"393","article-title":"Primary biliary cirrhosis: contribution of HLA class II allele DR8.","volume":"86","author":"Gregory","year":"1993","journal-title":"Q J Med"},{"key":"R38-18-20250124","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/lt.20123","article-title":"Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.","volume":"10","author":"Neuberger","year":"2004","journal-title":"Liver Transpl"},{"key":"R39-18-20250124","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/01.TP.0000090867.83666.F7","article-title":"The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation.","volume":"76","author":"Sanchez","year":"2003","journal-title":"Transplantation"},{"key":"R40-18-20250124","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/jlts.2003.50132","article-title":"The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation.","volume":"9","author":"Levitsky","year":"2003","journal-title":"Liver Transpl"},{"key":"R41-18-20250124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hep.1840210107","article-title":"Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.","volume":"21","author":"Sheiner","year":"1995","journal-title":"Hepatology"},{"key":"R42-18-20250124","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.20213","article-title":"Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.","volume":"10","author":"McTaggart","year":"2004","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20511","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200510000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:04:58Z","timestamp":1737734698000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200510000-00018"}},"subtitle":["Peritransplant Factors and Ursodeoxycholic Acid Treatment Post-Liver Transplant"],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20511","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}